Ryan Scott
Advertisement
Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com
Articles by Ryan Scott
Advertisement
Latest Updated Articles
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCCPublished: June 2nd 2024 | Updated:
Biomarker Developments Continue to Shape Immunotherapy Treatment Paradigm for GI CancersPublished: February 11th 2022 | Updated:
Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCLPublished: May 20th 2024 | Updated:
ECOG-ACRIN Works to Improve Representation of Minority Populations in Cancer Clinical TrialsPublished: February 28th 2022 | Updated:
Zandelisib/Zanubrutinib Produces Promising Safety, Efficacy in Relapsed/Refractory B-Cell MalignanciesPublished: August 18th 2021 | Updated:
Mesenchymal Chondrosarcoma Is a Rare Sarcoma Subtype With Challenging DiagnosisPublished: March 2nd 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5